Literature DB >> 24434240

Hepatitis E: an emerging disease.

María Teresa Pérez-Gracia1, Beatriz Suay2, María Luisa Mateos-Lindemann3.   

Abstract

Currently, the infection with the hepatitis E virus represents the most frequent cause for acute hepatitis and jaundice in the world. According to WHO estimations, around two billion people, representing one third of the world's population, live in endemic areas for HEV and, therefore, are at risk of infection. In developed countries, the circulation of the virus in both human and animal (swine, boar, deer) sewage has been confirmed; however, the incidence rate is low compared to that of developing countries where outbreaks of acute hepatitis transmitted via the fecal-oral route are originated, more frequently in the flooding season or after natural disasters, combined with deficient sanitary conditions. There are currently 4 known genotypes of HEV. Genotypes 1 and 2 are isolated in all human epidemic outbreaks in developing countries, while genotypes 3 and 4 are isolated not only in humans but also in animals, in both developing and industrialized countries. These data support genotypes 3 and 4 having zoonotic nature. The diagnosis of this disease is based in the detection of anti-HEV IgG and IgM in blood serum using enzyme-linked immunosorbent methods. However, the method that best confirms the diagnosis is the RT-PCR, which detects HEV RNA in blood serum and also provides the genotype. The clinical course is generally that of an acute hepatitis which in some cases may require hospitalization and that, in transplant patients or HIV infected individuals can become a chronic hepatitis. Furthermore, the virus constitutes an important risk for pregnant women. The hepatitis E can present a wide range of symptoms, from a subclinical case to chronic liver disease with extrahepatic manifestations. For this reason, the diagnostic is challenging if no differential diagnosis is included. There is no specific antiviral drug for hepatitis E, but satisfactory results have been observed in some patients treated with pegylated interferon alfa2a and/or ribavirin. This revision is an update of all the molecular, epidemiological, clinic and preventive knowledge on this emergent disease up to date.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HEV; Hepatitis E; Hepatitis E virus; Zoonotic disease

Mesh:

Year:  2014        PMID: 24434240     DOI: 10.1016/j.meegid.2014.01.002

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  33 in total

Review 1.  Hiding in Plain Sight? It's Time to Investigate Other Possible Transmission Routes for Hepatitis E Virus (HEV) in Developed Countries.

Authors:  Nicola J King; Joanne Hewitt; Anne-Marie Perchec-Merien
Journal:  Food Environ Virol       Date:  2018-04-05       Impact factor: 2.778

2.  Hepatitis E Virus in Surface Water, Sediments, and Pork Products Marketed in Southern Brazil.

Authors:  F H Heldt; R Staggmeier; J S Gularte; M Demoliner; A Henzel; F R Spilki
Journal:  Food Environ Virol       Date:  2016-05-12       Impact factor: 2.778

3.  A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions.

Authors:  Yueyuan Zhao; Xuefeng Zhang; Fengcai Zhu; Hui Jin; Bei Wang
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 4.  Hepatitis E: an old infection with new implications.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Maria Bianchi; Gabriele Calizzani; Fabio Candura; Liviana Catalano; Blandina Farina; Monica Lanzoni; Vanessa Piccinini; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

5.  CD8+ lymphocytes but not B lymphocytes are required for protection against chronic hepatitis E virus infection in chickens.

Authors:  Eda Rogers; Stephanie Michelle Todd; Frank William Pierson; Scott P Kenney; Connie Lynn Heffron; Danielle M Yugo; Shannon R Matzinger; Elena Mircoff; Irene Ngo; Charles Kirby; Michaela Jones; Paul Siegel; Peter Jobst; Karen Hall; Robert J Etches; Xiang-Jin Meng; Tanya LeRoith
Journal:  J Med Virol       Date:  2019-07-25       Impact factor: 2.327

6.  Hepatitis E virus infections in travellers: assessing the threat to the Australian blood supply.

Authors:  Ashish C Shrestha; Robert L P Flower; Clive R Seed; Anthony J Keller; Veronica Hoad; Robert Harley; Robyn Leader; Ben Polkinghorne; Catriona Furlong; Helen M Faddy
Journal:  Blood Transfus       Date:  2016-07-22       Impact factor: 3.443

7.  In-silico design and molecular docking evaluation of peptides derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of Hepatitis E virus capsid protein.

Authors:  Carolina Quintero-Gil; Jaime Parra-Suescún; Albeiro Lopez-Herrera; Sergio Orduz
Journal:  Virusdisease       Date:  2017-06-09

8.  Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.

Authors:  Osmany Larralde; Juraj Petrik
Journal:  Med Microbiol Immunol       Date:  2017-04-22       Impact factor: 3.402

9.  Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.

Authors:  Heléne Norder; Marie Karlsson; Åsa Mellgren; Jan Konar; Elisabeth Sandberg; Anders Lasson; Maria Castedal; Lars Magnius; Martin Lagging
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

10.  Viral Macro Domains Reverse Protein ADP-Ribosylation.

Authors:  Changqing Li; Yannick Debing; Gytis Jankevicius; Johan Neyts; Ivan Ahel; Bruno Coutard; Bruno Canard
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.